ResTORbio Pins Hopes On Parkinson’s After Failed CSRI Study
Investors Seem Wary Of Its Prospects, However
Company terminates studies of its TORC1 blocker after it fails to prevent respiratory illness in elderly patients with clinically symptomatic respiratory illness (CSRI). ResTORbio is hoping the same drug will be effective in Parkinson’s disease.
